Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
Stock Information for Seelos Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.